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treated with PIO 30 mg/MF rather than SU/MF, one
death was avoided (after 15 years of treatment). PIO was
more expensive, but this was in part offset by a reduction
in complications. The average undiscounted patient life-
time additional cost of treatment with PIO combinations
over their alternatives ranges from 9421 Denmark Kroner
(DKK) to a maximum of 74,687DKK. The incremental cost
per life year gained of PIO 30 mg/MF relative to SU/MF,
and RSG 8 mg/MF is 208,657DKK and 167,060DKK,
respectively.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and repre-
sents a cost-effective use of scarce resources when judged
against other therapeutic interventions. It is necessary to
confirm the results of this theoretical model once long-
term effectiveness data with the compared alternatives
are available.
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OBJECTIVES: The treatment of diabetic foot ulcers is
extremely costly and such ulcers have potentially pro-
found consequences for the patient. Apligraf, a living hu-
man skin equivalent, has been shown in clinical trials to
be effective in the management of DFUs resistant to stan-
dard care. However, such trials provide little or no infor-
mation about long-term costs. We attempt to estimate the
costs of treatment in the Netherlands with standard care
and the cost-effectiveness of Apligraf.
METHODS: A Markov chain model was developed to
compare the treatment costs of standard care (good
wound care) with Apligraf for treatment of diabetic foot
ulcers. The states in the model relate to the condition of
the ulcer and the amputation status of the patient. Tran-
sition probabilities were calculated using data from the
Apligraf DFU pivotal study and other published litera-
ture. Cost data were drawn from a number of sources in
the Netherlands.
RESULTS: The monthly cost of treating an uninfected ul-
cer is 432 Euros, while treating an infected or gangrenous
ulcer costs 1963 and 2359 Euros per month, respectively.
Amputation costs range from 7582 Euros (toe) to 15,810
Euros (whole foot). For patients receiving good wound
care, the annual cost of care is 4775 Euros. The results
suggest that costs incurred in using Apligraf are recov-
ered within about a year of initiating treatment. Patients
receiving Apligraf experience improved healing rates and
fewer amputations. As a result, Apligraf was more cost-
effective than good wound care.
CONCLUSION: Apligraf promises to be a cost-effective
treatment for patients with DFU resistant to normal care.
More rapid healing and reduced number of amputations
mean that patients will have a better quality of life. Fur-
ther studies are needed to examine the long-term costs
and effects of Apligraf.
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OBJECTIVES: Treatment costs for type 2 diabetic pa-
tients in Germany amount to more than 31 billion DM
per year, mainly because of related complications. In ac-
cordance with the St. Vincent declaration, these compli-
cations should be reduced at least by one third by treat-
ing according to current guidelines.
METHODS: The CODE-2 study results described the ac-
tual treatment of diabetic patients and associated costs. This
analysis focuses on those 47% of diabetic patients who had
no complications, with the aim of preventing long-term
complications in these patients. The European Diabetes Pol-
icy Group guidelines were applied to define the optimal
therapy regarding blood glucose, lipids and blood pressure.
Costs of guideline-related medication (antidiabetic, lipid
lowering agents and antihypertensive drugs) and costs of ad-
ditional outpatient treatment were calculated using official
tariffs. These results were compared to the cost of current
treatment as assessed in CODE-2.
RESULTS: Guideline treatment would induce 1270 DM
cost per patient for additional medication and outpatient
treatment. For office-based physicians who treat nearly
10% of their patients for diabetes, that would mean a
budget increase of nearly 90,000 DM per year for each
physician. Thus, for all of Germany annually about 2.1
billion DM would have to be invested in diabetes patients
who do not have complications.
CONCLUSIONS: Treatment of patients with type 2 dia-
betes according to the guidelines makes a huge invest-
ment necessary. Nevertheless, this could be balanced by
avoiding long-term complications in the future. Assum-
ing optimal treatment according to guidelines could pre-
vent one third of late diabetes-related complications and
by using the published data of the CODE-2 study, poten-
tial cost savings of 2.9 billion DM could be achieved,
which actually exceeds the cost of prevention.
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OBJECTIVE: The IDNT trial demonstrated that irbe-
sartan slows progression to end-stage renal disease
(ESRD) in patients with type 2 diabetes compared to am-
lodipine and control, defined as placebo in addition to
other antihypertensive therapies. Treatment of ESRD is
very expensive, costing  $50,000 USD/year/patient, and
diabetes is the most common underlying etiology. The
purpose of this analysis was to estimate the economic im-
pact of irbesartan in this population of patients.
METHODS: For the economic analysis, study endpoints
were defined as ESRD or imputed ESRD derived from the
observation of a doubling of serum creatinine (DSC),
which has been shown to predict ESRD. For the imputed
estimate, we applied the observed median follow-up time
between DSC and ESRD to impute time to ESRD in pa-
tients who experienced DSC without ESRD. Kaplan-
Meier survival estimation was then applied to these data
stratified by treatment. The difference in cumulative inci-
dence rates at three years was used to assess the absolute
risk reduction (ARR) in averting ESRD between treat-
ment arms. The ARR was used to calculate the number
of ESRD events averted. Using data from the NHANES
III survey, we then estimated the number of IDNT-eligi-
ble patients in the US. Based on the year 2000 Annual
Data Report for the United States Renal Data System, a
yearly ESRD cost/patient of $52,649 was utilized.
RESULTS: We estimated the ARR for our endpoint to be
6.4% at three years for irbesartan versus control. Approx-
imately 550,000 NHANES III subjects met the IDNT eligi-
bility criteria. Compared to control, irbesartan treatment
would prevent approximately 35,000 cases of ESRD, at
cost savings of 2.5 billion dollars over three years.
CONCLUSION: Treatment of IDNT-eligible patients
with irbesartan has the potential of generating large sav-
ings for the US health-care system.
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OBJECTIVES: This study examines factors associated
with drug treatment changes after an HbA1c test in a pri-
vately insured sample of diabetes patients in Califor-
nia, USA.
METHODS: Diabetes patients were selected from a phy-
sician organization with approximately 1600 physicians
and 220,000 patients. Electronic records of HbA1c test
results, prescriptions, inpatient and outpatient visits, and
enrollment periods from 1/1/1997 through 9/30/2000
were collected for patients enrolled in two affiliated
Health Maintenance Organizations. Patients in the final
sample had at least one HbA1c test result and were en-
rolled for 120 days after (observation period) and 12
months before (baseline period) their most recent test.
Diabetes comorbidities, drug class, and therapy days (a
proxy for compliance/persistence) were determined for
the baseline period. A logistic regression tested whether
these factors or patient demographics were associated
with addition or discontinuation of diabetes drug classes
following the test.
RESULTS: Of the 7104 diabetes patients in the database,
2643 (37.2%) met all criteria for the final sample. Mean age
was 64.6 years (SD  14.3), and 49.9% of the population
was female. Patients’ baseline period drug treatments in-
cluded insulin alone (n  246, 9.3%), sulfonylureas alone
(n  649, 24.6%), metformin alone (n  195, 7.4%), sulf-
met combination (n  536, 20.3%), other multiple (n 
233, 8.8%) and no therapy (n  784, 29.7%). Overall, 599
(22.6%) patients changed treatments. Higher HbA1c levels
predicted increased rates of treatment change (Odds Ratio
[OR]1.22 per 1-point HbA1c difference, p  .0001). Rel-
ative to patients with no drug treatment, patients receiving
oral drug treatment were more likely to change treatments
(OR range 14.4–33.1, all p  .0001). Compliance/persis-
tence with oral treatments during the baseline period pre-
dicted a lower rate of treatment changes (OR range 0.04–
0.09, all p  .0004).
CONCLUSIONS: Patients with higher HbA1c test re-
sults are more likely to change drug treatment, suggesting
appropriate physician responses to inadequate glycemic
control. Compliance/persistence appears to affect the de-
cision to change oral treatments.
PDG19
TRENDS IN USE OF ANTIDIABETICS IN THE 
CZECH REPUBLIC
Sechser T, Pelikanova T
Institute for Clinical and Experimental Medicine, Prague, Czech 
Republic
OBJECTIVE: Diabetes mellitus affects over 600,000 peo-
ple in the Czech republic. The treatment algorithms for
diabetic patients currently used in the Czech Republic are
in agreement with the international recommendations.
We compared data on consumption of antidiabetics (in-
sulin and oral antidiabetics) in the Czech republic with
that in other countries.
METHODS: Data on insulin and oral antidiabetic drug
consumption were expressed in terms of defined daily
doses per 1000 inhabitants per day (i.e. DDD/1000 inh/d).
RESULTS: Insulin consumption is slowly increasing. Con-
sumption of sulphonylureas is slowly decreasing while
that of biguanides is increasing. The proportion of met-
formin use is more than 50% above that of biguanides.
CONCLUSION: It follows from the present comparisons,
